Previous 10 | Next 10 |
- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 - SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focu...
89bio (ETNB): Q4 GAAP EPS of -$0.63 beats by $0.25.Cash, cash equivalents, and short-term investments of $204.7M.Press Release For further details see: 89bio EPS beats by $0.25
- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - - NASH histology cohort topline data expected by YE21 - - Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in 2H21 - SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ...
89bio ([[ETNB]] +4.4%) has revealed the additional data from its Phase 1b/2a study of BIO89-100 in patients with nonalcoholic steatohepatitis (“NASH”).The results to be presented in a poster presentation at the ongoing Endocrine Society’s annual meeting indicates that BIO...
SAN FRANCISCO, March 20, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional positive dat...
SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s M...
SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s M...
SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Ma...
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Ma...
BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated. Cash position is decent but not adequate to reach the market. For further details see: 89bio: NASH Drug Developer With Differentiated...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...